Beckman coulter and fujirebio partner to bolster access to patient-friendly, blood-based alzheimer's disease test

Collaboration builds upon fujirebio expertise in neurodegenerative disease assays and beckman coulter's high sensitivity, high throughput, global installed base of access family of immunoassay analyzers brea, calif. and tokyo , july 17, 2023 /prnewswire/ -- beckman coulter diagnostics, a clinical diagnostics leader, and fujirebio, a leader in neurological markers and in vitro diagnostic (ivd) manufacturing, today announced a new partnership combining their respective immunoassay strengths to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in the field of neurodegenerative diseases.
DHR Ratings Summary
DHR Quant Ranking